Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Steps Up Campaign Against Rx Imports; Bill “Technically” Flawed

Executive Summary

Pending federal legislation to allow importation of prescription drugs from Canada would create unworkable conflicts with state pharmacy laws, FDA Commissioner Mark McClellan told the National Association of Boards of Pharmacy legislative conference Sept. 14 in Washington, D.C

You may also be interested in...



Illinois Reimportation Plan Goes Beyond Canada, Enlists PBM

Illinois will contract with a non-domestic PBM to administer personal drug reimportation from Ireland, the United Kingdom and Canada

Illinois Reimportation Plan Goes Beyond Canada, Enlists PBM

Illinois will contract with a non-domestic PBM to administer personal drug reimportation from Ireland, the United Kingdom and Canada

FDA warns drug importers

FDA issues Jan. 22 warning letter to Temple, Texas-based Expedite Rx and affiliated companies SPC Global Technologies and Employer Health Options for selling prescription drugs imported from Canada. In the letter, FDA says Expedite Rx' web site is "misleading" for stating that FDA has taken a "compassionate approach" to enforcement. FDA has said it is stepping up investigations of imported drugs, and has made several well-publicized seizures of drug repackagers (1"The Pink Sheet" Sept. 22, 2003, p. 3)...

Related Content

UsernamePublicRestriction

Register

PS042495

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel